Renin-angiotensin system at the heart of COVID-19 pandemic.

Biochimie. 2020 Apr 16;174:30-33.

Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19.

N Engl J Med. 2020 Apr 23;382(17):1653-1659.

Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.

Drug Dev Res. 2020 Mar 4.

Controversies of renin–angiotensin system inhibition during the COVID-19 pandemic.

Nat Rev Nephrol. 2020 Apr 3.

Might renin–angiotensin system blockers play a role in the COVID-19 pandemic?

Eur Heart J Cardiovasc Pharmacother. 2020 Apr 14. pii: pvaa030

Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus.

J Virol. 2020 Mar 17;94(7). pii: e00127-20

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.

Cell 181, 1–10, April 16, 2020.

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2.

Science. 2020 Mar 27;367(6485):1444-1448

doi: 10.1126/science.abb2762

Risks of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence.

Clin Pharmacol Ther. 2020 Apr 22.

Binding of SARS-CoV-2 and angiotensin-converting enzyme 2: clinical implications.

Cardiovasc Res. 2020 Apr 17.

Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension.

High Blood Press Cardiovasc Prev. 2020 Apr;27(2):105-108.

Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients.

Elife. 2020 Apr 6;9. pii: e57278.

doi: 10.7554/eLife.57278